Data extracted from three relapse prevention studies failed to show significant effects of
agomelatine over placebo (relative risk 0.78, 99 % Cl 0.41 − 1.48).
Secondary efficacy analyses showed a significant advantage of
agomelatine over placebo in terms of response (with no effect for remission).
Not exact matches
Acute treatment with
agomelatine was associated with a statistically significant superiority
over placebo of − 1.51 HRSD points (99 % Cl − 2.29 to − 0.73, nine studies).